共查询到20条相似文献,搜索用时 984 毫秒
1.
2.
3.
二十世纪七十年代,顺铂作为抗肿瘤药物在临床上的广泛使用,使无机过渡金属配合物的抗肿瘤活性成为生物医药领域的研究热点之一;随后研究者在数千个铂系金属配合物中又筛选出了毒性相对较低的广谱抗肿瘤药物卡铂和环硫铂[1].但是临床上化疗药物的疗效、毒副作用和肿瘤细胞的耐药性等问题仍是生物医药领域亟待解决的关键问题之一.钌和钌配合物在生物体内易于吸收和代谢,属于低毒性的化合物;而且钌配合物具有与铂配合物相似的分子结构,能够以插入方式、沟结合方式和静电作用方式与DNA分子交联,干扰核酸的生物功能.国际上已普遍认为,钌配合物将成为最有前途的抗肿瘤药物之一[2]. 相似文献
4.
5.
端粒酶在肿瘤细胞中高表达,已经成为抗肿瘤药物的重要靶点,由于很多肿瘤细胞中富含G4-DNA,通过稳定G-四链体DNA的形成来抑制端粒酶的活性已成为抗癌药物的一个新策略. 本文设计了两种钌配合物,调查了这两种钌配合物稳定G4-DNA的能力,发现配合物2稳定端粒 G4-DNA的能力强于配合物1,配合物2能够诱导端粒 G4-DNA发生构型的转化,而配合物1不能诱导G4-DNA发生构型的转化,这项研究结果证明,钌配合物与G4-DNA的作用能力与配体的平面性有关. 在抗肿瘤活性方面,配合物2表现出更强的抗肿瘤活性,尤其是对HepG2细胞具有较强的抑制作用,推测其是以端粒酶为靶点发挥的抗肿瘤作用. 配合物2能够诱导肿瘤细胞凋亡,能诱导G1期细胞阻滞和DNA碎片的形成(细胞凋亡的特征). 据此推测本论文设计的钌配合物是一个潜在的抗肿瘤药物. 相似文献
6.
7.
自从钌元素问世以来,钌元素的合金和化合物在各类材料领域都发挥了巨大作用。简要介绍了钌元素的发现、钌合金和无机化合物/金属-有机配合物在电致发光器件、太阳能电池、抗肿瘤药物等领域的应用。 相似文献
8.
9.
10.
11.
12.
三价金配合物抗肿瘤活性研究* 总被引:1,自引:0,他引:1
三价金配合物具有潜在的抗肿瘤活性,是目前金属药物领域的研究热点。本文按配位原子的不同总结了稳定三价金配合物的结构特征,按其生物活性的构效关系、生物靶点和作用机制综述了三价金配合物抗肿瘤活性研究的最新成果:配体的结构特点以及离去基团对三价金配合物的体外细胞毒性影响较大;介绍了用于检测三价金配合物与可能的生物靶分子之间的相互作用的多种物理和生物学方法,重点关注了相互作用的模式,如嵌入/静电吸引/共价结合等,并解释了三价金配合物抗肿瘤活性的原因。最后提出了一些研究新思路,以期有助于设计得到靶标明确的具有良好药理活性的抗肿瘤药物。 相似文献
13.
由于优越的光物理和光化学特性,很多金属配合物长期以来被用于生物传感器、生物探针和医学诊断等领域。本文综述了近年来已经或有望成功应用于生命科学基础研究和临床医学诊断众多领域中的多种金属配位化合物,包括几种在成功商业化的体外诊断系统中作为分子探针、生物标记物或蛋白染色剂而广泛应用的金属钌配位化合物和稀土金属配位化合物,在核磁共振成像技术中作为造影剂或影像增强剂的系列金属钆配位化合物,以及在细胞成像、生物标记和蛋白质分析应用中极具商业化应用前景的一些新型环金属铱配位化合物等。此外,本文还对金属配合物结合纳米结构及技术在生物医学领域中的应用作了简单介绍和展望。 相似文献
14.
以酰腙为配体钒的单核、双核配合物因其结构丰富、生物活性多样而引起广泛关注。目前该领域新配合物的合成、表征和生物活性的研究甚为活跃。本文回顾了近年来钒酰腙配合物的研究状况,主要从以下三个方面进行综述:(1)钒酰腙配合物的合成方法;(2)此类配合物的配位模式;(3)一些单、双核钒酰腙配合物抗变形虫,抗肿瘤,类胰岛素,抑制Na+, K+-ATP酶,与DNA作用的生物活性。文中着重阐述了钒酰腙化合物的结构和生物活性之间的关系。此外,还提出了钒酰腙配合物研究领域的不足之处并对其今后发展方向进行了展望。 相似文献
15.
Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and two of them have entered clinical trials. Compared to platinum drugs, the complexes based on ruthenium are often identified as less toxic and capable of overcoming the resistance induced by platinum drugs in cancer cells. These activities were attributed to the transportation to tumour cells by transferrin and to the selective activation to more reactive species by the reducing environment of solid tumours as compared to healthy tissues. Ruthenium anticancer drugs have been almost always designed to mimic platinum drugs, particularly for targeting DNA. Indeed, none of the above properties has never been clearly demonstrated even for the ruthenium drugs that entered clinical trials. The suggestion for the future is to change the perspective when designing new chemical entities, abandoning the philosophy that guided the actual panel of ruthenium drugs and to look further into the fine mechanism by which the most relevant ruthenium complexes available kill the target tumour cells, then focusing on targets selective of tumour cells and responsible for cell growth and malignancy. 相似文献
16.
《Journal of Coordination Chemistry》2012,65(24):4332-4346
In the search for antitumor active metal complexes several ruthenium complexes have been reported to be promising. A series of mononuclear Ru(II) complexes, [Ru(T)2(S)]2+, where T?=?2,2′-bipyridine/1,10-phenanthroline and S?=?CH3-bitsz, Cl-bitsz, Br-bitsz, tmtsz, dmtsz, have been prepared and characterized by UV-Vis, IR, 1H-NMR, FAB-mass spectroscopy, and elemental analysis. The complexes were subjected to in vivo anticancer activity against a transplantable murine tumor cell line Ehrlich's ascitic carcinoma (EAC) and in vitro cytotoxic activity against human cancer cell line Molt 4/C8, CEM, and murine tumor cell line L1210. Ruthenium complexes showed promising biological activity especially in decreasing tumor volume and viable ascitic cell counts. Treatment with these complexes prolonged the life span of EAC-tumor-bearing mice by 10–48%. In vitro evaluation of these ruthenium complexes revealed cytotoxic activity from 0.21 to 24?µmol?L?1 against Molt 4/C8, 0.16–19?µmol?L?1 against CEM, and 0.75–32?µmol?L?1 against L1210 cell proliferation, depending on the nature of the compound. 相似文献
17.
《Coordination chemistry reviews》2003,236(1-2):209-233
The well-developed synthetic chemistry of ruthenium, particularly with ammine, amine and imine ligands, provides for many approaches to innovative new metallopharmaceuticals. Advantages of utilizing ruthenium am(m)ine complexes in drug development include, (1) reliable preparations of stable complexes with predictable structures; (2) the ability to tune ligand affinities, electron transfer and substitution rates, and reduction potentials; and (3) an increasing knowledge of the biological effects of ruthenium complexes. Many Ru(II) and Ru(III) am(m)ine complexes selectively bind to imine sites in biomolecules. Collectively, these lend ruthenium complexes to redox-activation and photodynamic approaches to therapy as well as the development of radiopharmaceuticals containing one of several radionuclides of ruthenium. Ruthenium red and the related Ru360 strongly inhibit calcium ion uptake in the mitochondria. A number of ruthenium compounds with anticancer activity appear to penetrate tumors through a transferrin-mediated process and bind to cellular DNA following intracellular activation by reduction. Ruthenium complexes exhibit both nitric oxide release and scavenging functions that can affect vasodilation and synapse firing. Simple ruthenium complexes are unusually effective in suppressing the immune response by inhibiting T cell proliferation. 相似文献
18.
Martin A. Dolan Alexandre D.C. Dixon John D. Chisholm Daniel A. Clark 《Tetrahedron letters》2018,59(51):4471-4474
Ruthenium–catalyzed enyne metathesis is a reliable and efficient method for the formation of 1,3-dienes, a common structural motif in synthetic organic chemistry. The development of new transition-metal complexes competent to catalyze enyne metathesis reactions remains an important research area. This report describes the use of ruthenium (IV) dihydride complexes with the general structure RuH2Cl2(PR3)2 as new catalysts for enyne metathesis. These ruthenium (IV) dihydrides have been largely unexplored as catalysts in metathesis-based transformations. The reactivity of these complexes with 1,6 and 1,7-enynes was investigated. The observed reaction products are consistent with the metathesis activity occurring through a ruthenium vinylidene intermediate. 相似文献
19.
20.
Ruthenium(III) and osmium(VIII) form coloured complexes with 4–amino ?2-mercapto-5-nitroso-6-pyrimidinol (ammonium salt). The complexes have been spectrophotometrically studied and made use of in determination of the two metals; the reaction with ruthenium is particularly sensitive (0.006 μg of ruthenium/cm2for 0.001 absorbance). Many ions do not interfere in the determination. 相似文献